
Cystatin C, Creatinine eGFR Gap Flags Higher Mortality, HF Risk
Key Takeaways
- Large negative eGFR discordance (eGFRcys ≥30% below eGFRcr) was common and heterogeneous across outpatient cohorts, ranging from 2.8% to 49.8%, and frequent in hospitalized patients.
- Comorbidity burden and kidney injury markers correlated with discordance, including diabetes, HF, PAD, COPD, liver disease, smoking, and higher albuminuria, with inconsistent gradients across eGFRcr strata.
Among 821,327 outpatients, cystatin C–based eGFR at least 30% below creatinine-based eGFR was linked to higher death and heart failure rates.
Outpatients whose cystatin C–based
The individual participant–level meta-analysis drew on 23 outpatient cohorts (821,327 participants; mean age, 59 years; 48% female) and 2 inpatient cohorts (39,639 patients; mean age, 67 years; 31% female) in the Chronic Kidney Disease Prognosis Consortium (CKD-PC). All participants had concurrent creatinine and cystatin C measurements. The researchers defined a large negative difference as an estimated glomerular filtration rate based on cystatin C (eGFRcys) at least 30% lower than an eGFR based on creatinine (eGFRcr).
Creatinine-based estimates remain the standard starting point. The
Discordance Common in Outpatients, More So in Hospitals
About 11% of outpatients had a large negative difference, and 3.8% had a large positive difference. Among hospitalized patients, about 35% had a large negative difference. The share of outpatients with a large negative difference varied widely by cohort, from 2.8% to 49.8%.
In outpatients, older age,
Large Negative Gap Linked to Higher Mortality and HF Rates
Compared with outpatients whose eGFR difference fell between –30% and 30%, those with a large negative difference had higher rates of all-cause mortality (28.4 vs 16.8 per 1000 person-years; HR, 1.69; 95% CI, 1.57-1.82) and cardiovascular mortality (6.1 vs 3.8 per 1000 person-years; HR, 1.61; 95% CI, 1.48-1.76).
They also had higher rates of atherosclerotic cardiovascular disease (13.3 vs 9.8 per 1000 person-years; HR, 1.35; 95% CI, 1.27-1.44), HF (13.2 vs 8.6; HR, 1.54; 95% CI, 1.40-1.68), and kidney failure with replacement therapy (2.7 vs 2.1; HR, 1.29; 95% CI, 1.13-1.47). Models adjusted for demographics, comorbidities, body mass index, eGFRcr category, and albuminuria.
The kidney failure finding did not hold when models adjusted for eGFRcr-cys instead of eGFRcr; in that sensitivity analysis, the association reversed (HR, 0.73; 95% CI, 0.64-0.84). The associations with mortality and cardiovascular outcomes persisted, with smaller estimates.
Implications for Cystatin C Testing and Lab Reporting
The authors wrote that cystatin C testing identifies many people whose GFR may be worse than eGFRcr alone would suggest and that these patients may benefit from a more precise GFR estimate for clinical decision-making. They added that the findings support laboratories reporting eGFRcys and eGFRcr-cys alongside eGFRcr, and they pointed to older adults and people with conditions such as HF or liver disease as groups for whom cystatin C testing may be informative.
The study had limitations. Creatinine and cystatin C measurement methods differed across cohorts, outcomes relied largely on diagnosis codes, and data on confounders such as muscle mass were unavailable. The UK Biobank made up about half of the outpatient population and was more than 90% White, although excluding it produced similar results. Long-term outcomes were not evaluated in hospitalized patients.
“In the CKD-PC, 11% of outpatient participants and 35% of hospitalized patients had an eGFRcys that was at least 30% lower than eGFRcr,” wrote the researchers of the study. “In the outpatient setting, presence of eGFRcys at least 30% lower than eGFRcr was associated with significantly higher rates of all-cause mortality, cardiovascular events, and kidney failure.”
References
- Estrella MM, Ballew SH, Sang Y, et al. Chronic kidney disease prognosis consortium investigators and collaborators. Discordance in creatinine- and cystatin C–based eGFR and clinical outcomes: a meta-analysis. JAMA. 2025;334(21):1915-1926. doi:10.1001/jama.2025.17578
- KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 Apr;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018
Related to this article








